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Abstract. 
Extracellular vesicles (EVs) are released by 
most cell types and have been associated with 
multiple immunomodulatory functions. MHC 
class I molecules have crucial roles in antigen 
presentation and in eliciting immune 
responses and are known to be incorporated 
into EVs. However, the MHC class I 
immunopeptidome of EVs has not been 
established. Here, using a small-scale 
immunoisolation of the antigen serotypes 
HLA-A*02:01 and HLA-B*27:05 expressed 
on the Epstein–Barr virus–transformed B cell 
line Jesthom and MS of the eluted peptides 
from both cells and EVs, we identified 516 
peptides that bind either HLA-A*02:01 or 
HLA-B*27:05. Of importance, the predicted 
serotype-binding affinities and peptide-anchor 
motifs did not significantly differ between the 
peptide pools isolated from cells or EVs, 
indicating that during EV biogenesis, no 
obvious editing of the MHC class I 
immunopeptidome occurs. These results, for 
the first time, establish EVs as a source of 
MHC class I peptides that can be used for the 
study of the immunopeptidome and in the 
discovery of potential neoantigens for 
immunotherapies. 
 
Introduction. 
    Extracellular vesicles (EVs), including 
those known as exosomes, are released by 
many types of cells, and have been ascribed 
numerous functions in cellular 
communication, including the propagation of 
niche sites for tumour metastases (1), 
facilitating viral infection (2) and in 
angiogenesis (3), amongst many others. EVs 
are thought to originate from multivesicular 
bodies and are secreted following fusion of 
multivesicular bodies (MVB) with the plasma 
membrane (4,5). 
    Within the immune system EVs have been 
reported to have mostly immunoinhibitory 
functions (6), although dendritic cell- and 
tumour cell-derived EVs have shown some 
promise in the stimulation of anti-tumour 
responses (7). EVs have also been 
demonstrated to have a role in transplantation 
responses, leading to a reassessment of the 
passenger leukocyte hypothesis (8) and have 
been demonstrated to influence thymic 
selection (9). These physiological and 
therapeutic roles in the immune system imply 
that peptide presentation by Major 
Histocompatibility Complex (MHC) 
molecules on EVs have a profound effect on 
their role in eliciting immune responses. To 
date, no information exists on the peptide 
repertoire that is presented by EVs. MHC 
expression and peptide presentation by EVs 
could be an important determining factor for 
their general effectiveness, as they could 
modulate EV-immune cell interactions, which 
potentially may affect their therapeutic value. 
    In relation to the Major Histocompatibility 
Complex (MHC) class I system proteins and 
their role as antigen presenting molecules to 
CD8+ T cells, we have previously shown that 
MHC class I molecules are incorporated into 
EVs from a number of cell lines, including 
the Jesthom line used in the current study (10-
12). However, their ability to modulate CD8+ 
activity has not been studied in detail, 
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although EVs loaded exogenously with 
common immunogenic viral peptides can 
stimulate IFNγ and TNFα release from 
purified human CD8+ T cells, indicating EVs 
can directly impact on the behaviour of these 
cells (13). 
    In order to further understand the role of 
MHC class I on EVs we have undertaken here 
to determine their immunopeptidome, i.e. the 
repertoire of the peptides being presented. 
The null hypothesis would be that the EV 
pool of MHC class I bound peptides would be 
an exact copy of those present on the cell 
surface. However, since EVs can be derived 
from an endocytic route involving the 
formation of MVB, editing of the peptide 
repertoire could occur, by dissociation of 
weak affinity peptides and/or loading of 
peptides from within the MVB compartment, 
thus generating potential EV-associated 
neoantigens. This could be of significant 
importance in the search for novel MHC class 
I epitopes and development of patient-tailored 
immunotherapies.  
    In this study we have performed small 
scale MHC class I immunoisolation and 
peptide extraction to determine the repertoire 
of peptides from EVs of the EBV-
transformed B cell line Jesthom, providing 
the first data that EVs can be used as a source 
for immunopeptidomic studies of MHC class 
I epitopes in health and disease. 
 
Results 
     The EBV-transformed B cell line Jesthom 
expresses HLA-A*02:01 and HLA-B*27:05. 
Three small-scale immunoisolation 
experiments were performed from 
approximately 250, 600 and 800 million 
Jesthom cells, yielding approximately 200, 
300 and 400  µg of EVs respectively. 
Importantly, cell lysates and EVs from the 
same culture were processed concomitantly to 
prevent temporal sample variations due to 
dissociation of low affinity peptides. EVs 
were isolated by standard procedures of 
filtration and ultracentrifugation. Immunoblot 
analysis of a sample of the cell and EV 
lysates indicated enrichment of MHC class I, 
and the prototypical EV markers CD9 and 
CD81 in the EV isolates, whereas the non-EV 
marker GRP78 (BiP) was present at very low 
levels in EVs (Figure 1A). From a series of 
cultures with approximately 10 million 
Jesthom cells, the enrichment of HLA-A 
molecules and HLA-B molecules in EV was 
between 1.8 and two-fold (Supplementary 
Figure 1). Nanoparticle tracking analysis 
(NTA), which utilises light scattering of 
particles in suspension undergoing Brownian 
motion, of culture supernatant after 0.2 µm 
filtration, but prior to ultracentrifugation 
indicated three typical peaks of around 61, 86 
and 142 nm (Figure 1B), with a mean of 151 
nm and mode of 115 nm from three 
preparations. The samples therefore represent 
typical EVs. From a separate test run of 400 
million Jesthom cells, an estimated 
concentration of 400 x 109 particles were 
detected by NTA, indicating the release of 
approximately 1,000 EV per cell over the 
course of 48 hours. 
    The cell and EV lysates were 
immunoisolated with the anti-HLA-A, -B and 
–C mAb W6/32, pre-absorbed (but not cross-
linked) to Protein-G agarose beads. After 
extensive washing, 2% of the beads were 
removed and analysed by SDS-PAGE and 
Coomassie blue staining or immunoblotting 
with the anti-HLA-B and –C specific mAb 
HC10. Compared to the control W6/32 (no 
lysate) sample additional bands at 
approximately 43 kDa were detected in both 
cell and EV samples (Figure 1C), which were 
HC10 reactive (Figure 1D). Additional bands 
were detected migrating at the dye front, 
which were presumed to be  β2-
microglobulin (Figure 1C). The remaining 
98% of the immunoisolated cell and EV 
samples were acidified in 0.5% TFA to 
denature the MHC class I molecules, and the 
low molecular mass peptide pool fraction 
isolated with Centricon 3 centrifugal filters. 
The isolated peptide fraction was then 
processed and analysed by mass 
spectrometry. 
    Identified peptides from the resulting 
MASCOT files between 8 and 13 amino acids 
long were analysed for HLA-A*02:01 and 
HLA-B*27:05 predicted binding affinity 
using the NetMHCcons 1.1 server, which 
combines three algorithms (NetMHC, 
NetMHCpan and PickPocket).  From the 
combined data of the three biological 
replicates 145 and 94 peptides were identified 
from HLA-B*27:05 cell and EV preparations 
respectively, and 172 and 105 peptides from 
HLA-A*02:01 cell and EV preparations 
respectively (Table 1 and Supplementary 
Table 1). In addition eleven HLA-C*01:02 
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(also expressed by Jesthom cells) peptides 
were also identified but are not reported here 
due to low numbers. The mean predicted 
binding affinity of the HLA-A*02:01 binding 
peptide pool was 33.3 nM for cells and 26.7 
nM for EVs (Figure 2A), and for the HLA-
B*27:05 binding peptide pool the mean 
predicted affinity was 225.9 nM for cells and 
199.5 nM for EVs (Figure 2C). Whilst this 
might suggest that there is a loss of some 
lower affinity peptides during the biogenesis 
of EVs, two tailed Mann Whitney tests 
indicated no significant differences between 
the cell and EV pools for either MHC class I 
allele (HLA-A*02:01, P = 0.8329 and HLA-
B*27:05, P = 0.3199 respectively).  Peptide 
lengths did not alter, with a predominance of 
9 mer peptides in both cells and EV for both 
HLA-A*02:01 and HLA-B*27:05 (Figure 2B 
and D). The anchor binding motifs were also 
analysed by Seq2logo for 9, 10 and 11 mer 
peptide pools from each source, with no 
significant alterations between the typical P2 
Leu and C-terminal Val/Leu anchors for 
HLA-A*02:01 (Figure 2E) and the P2 Arg 
and C-terminal Phe/Tyr anchors for HLA-
B*27:05 (Figure 2F). 26 of the 94 HLA-
B*27:05 peptides in the EV pool were not 
detected in the cell-derived pool, and 34 of 
the 105 HLA-A*02:01 peptides from EVs 
were not detected in the cell-derived pool 
(highlighted in red in Table 1), however the 
cellular origin of these peptides was mostly 
from the cytoplasm and nucleus, suggesting 
they would also appear in the cell derived 
pool in a larger sample size. One HLA-
A*02:01 binding peptide (LLLDVPTAAV) 
was identified from the endosome-located 
thiol-reductase GILT, but this has previous 
been reported in cells and therefore unlikely 
to be EV-specific (14). Taken together the 
data indicates that the MHC class I 
immunopeptidome of EVs is a replica of that 
found on the cell surface.  
 
Discussion. 
    Our data has several important 
implications. It demonstrates that the EV 
immunopeptidome is essentially identical to 
that of the cell of origin. As such, important 
antigenic peptides, such as viral or tumour 
associated antigens (TAA) and tumour 
specific antigens (TSA) are likely to be 
released in EVs, potentially subverting 
antigen specific CD8+ cytotoxic T cells at a 
distance from the infected cell or main 
tumour, thus potentially reducing effective 
CTL responses. The same observation would 
however also imply that EVs can be used as 
an effective source to isolate and detect TSA 
and TAA from readily available biological 
samples such as blood. EVs are known to be 
raised in pathological conditions (15,16), 
suggesting a relatively non-invasive 
technique for screening. As such, the EV-
derived peptidome can now be studied as a 
source for neoantigens for personalised 
immunotherapeutic approaches, as recently 
demonstrated in principle for melanoma solid 
tissue biopsies (17). Such identified peptides 
could then be utilised in dendritic cell 
exosome (DEX) based therapies (18), for 
which phase I and II trials have already been 
conducted. Furthermore this MS technique 
could be used to monitor the efficacy of 
target-peptide loading onto DEX. 
Our study does have some limitations. Our 
current small-scale study yielded a few 
hundred peptides, but larger samples and 
improved detection could yield thousands of 
identified peptides. The small, but consistent 
alteration in predicted binding affinities in the 
EV peptide pool would be worth studying in 
greater detail with such larger sample sizes. 
The residency time of an MHC class I 
complex during its incorporation into and 
secretion via an EV would be expected to 
promote the loss of low affinity peptides. 
Larger sample sizes would help resolve this 
issue. Furthermore, variations in the 
biogenesis of MVBs in different cell types 
could also have a significant impact upon the 
EV immunopeptidome. An extensive study of 
multiple cell types is now required. Of 
technical interest the antibody based 
immunoisolation of MHC molecules for 
peptide isolation utilised here is just one of 
several possible techniques (19). We have 
also performed preliminary studies on EV 
samples using mild acid elution (MAE), 
which in theory would not disrupt the cell or 
EV samples. The MAE technique removes 
the detergent lysis, immunoisolation and 
extensive washing steps that could lead to 
loss of low affinity peptides. However, MAE 
is known to produce increased peptide signals 
of non-MHC origin (20), but intriguingly we 
were able to detect some peptides with known 
binding motifs for the MHC class II 
molecules expressed on Jesthom cells (data 
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not shown), thus further enhancing the 
capacity of EVs to produce useful 
immunopeptidomic information. Taken 
together our study opens a new avenue for the 
characterisation of the immunopeptidome 
from highly biologically relevant vesicles. 
 
Experimental Procedures. 
Cell and EV isolation. 
    The EBV transformed B cell line (obtained 
from European Collection of Authenticated 
cell Lines no. 88052004) was grown in RPMI 
1640 (Invitrogen, UK) supplemented with 5% 
FBS (Invitrogen, UK). Once the required 
number of cells was obtained, the medium 
was replaced with serum free medium to 
prevent contamination from FBS derived 
exosomes (EX-Cell 610-HSF serum free, 
Sigma-Aldrich, UK) for 48 hours. Cells were 
then isolated by centrifugation (300 x g, 10 
min). The cells were washed once in PBS, 
then immediately resuspended in 5 ml lysis 
buffer (1% NP40, 150 mM NaCl, 10 mM Tris 
pH 7.6, with 1 mM PMSF). After 10 min on 
ice the lysates were centrifuged at 20,000 x g 
for 5 min and the supernatant stored on ice. 
10-20 µl was removed for immunoblotting. 
The EV containing supernatant was processed 
immediately by 0.2 µm filtration and 
ultracentifugation at 100,000 x g for 2 hours. 
The pellets were resuspended in 500 µl PBS 
and 10-20 µl removed for BCA protein 
estimation or EV characterisation by 
immunoblotting. The remaining bulk EV 
suspension was immediately lysed in 5 ml 
lysis buffer, as above. 
 
EV characterisation. 
    Nanoparticle tracking analysis was 
performed on a 0.5 ml cell culture sample 
after 0.2 µm filtration. Videos were taken 
using a Nanosight LM-10 unit (Malvern, 
UK), with 4 ms camera shutter and analysis 
detection threshold of 2 using NTA 2.3 
software. For immunoblotting, 5 µg of cell or 
EV lysates were run on 4-20% gels 
(Invitrogen) and transferred to nitrocellulose. 
Samples were incubated with the following 
antibodies overnight, HC10 (anti-HLA-B and 
–C), HCA2 (anti-HLA-A, a gift from Jacques 
Neefjes, Leiden), anti-GRP78 (dilution 
1:5000, code: STJ97526 St Johns 
Laboratories, UK), or anti-CD9 or –CD81 
(Thermofisher Scientific UK, codes: anti-
CD9 clone Ts9, dilution 1:5000, code 
15328354, CD81, dilution 1:5000, code 
15304032). Immunoblots were then incubated 
with 1:10,000 diluted IR Dye800cw anti-
mouse IgG (Licor, UK, code 925-32210) and 
visualised using a Licor Odyssey scanner. 
 
Immunoisolation of MHC class I peptides. 
    0.5 ml of Protein G –agarose (code 20399, 
binding capacity 11-15 mg/ml IgG, 
ThermoScientific UK) were pre-loaded with 
30 ml of W6/32 containing tissue culture 
supernatant for 20 min at room temperature, 
then washed twice in lysis buffer. The beads 
were then added to the cell and EV lysates 
and mixed for 1 hour at 4oC. Control W6/32 
loaded beads received lysis buffer alone. The 
beads were then washed with 60 volumes (3x 
10 ml) of lysis buffer without NP40. 10 µl of 
beads was then removed for reducing SDS-
PAGE and Coomassie blue staining (Gelcode 
Blue, ThermoScientific, UK). The remaining 
beads were resuspended in 1 ml 0.5 % TFA 
for 10 min at room temperature. The 
supernatant was then spun at 12,000 x g 
through pre-washed (in 0.1 % TFA) 
Centricon 3 filtration units (MerckMillipore, 
UK). The peptide containing flow through 
was then stored at -20oC until analysis by 
mass spectrometry. 
 
Mass spectrometry. 
    Peptides were concentrated using a C18 
column (NEST, ThermoScientific UK), 
eluted in 70% ACN/0.5% TFA and dried 
down by Speed Vac. Peptides were then 
analysed on an AB Sciex TripleTOF 5600+ 
system mass spectrometer (Sciex, 
Framingham, MA, USA) coupled to an 
Eksigent nanoLC AS-2/2Dplus system. The 
samples were loaded in loading buffer (2% 
acetonitrile and 0.05% trifluoroacetic acid) 
and bound to an Aclaim pepmap 100 µm × 2 
cm trap (Thermo Fisher Scientific), and 
washed for 10 min to waste after which the 
trap was turned in-line with the analytical 
column (Aclaim pepmap RSLC 75 µm × 15 
cm). The analytical solvent system consisted 
of buffer A (2% acetonitrile and 0.1% formic 
acid in water) and buffer B (2% water with 
0.1% formic acid in acetonitrile) at a flow rate 
of 300 nl/min with the following gradient: 
linear 1-20% of buffer B over 90 min, linear 
20-40% of buffer B for 30 min, linear 40-99% 
of buffer B for 10 min, isocratic 99% of 
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buffer B for 5 min, linear 99-1% of buffer B 
for 2.5 min and isocratic 1% solvent buffer B 
for 12.5 min. The mass spectrometer was 
operated in DDA top 20 positive ion mode, 
with 120 ms and 80 ms acquisition time for 
the MS1 (m/z 400-1250) and MS2 (m/z 95-
1800) scans respectively, and 15 s dynamic 
exclusion. Rolling collision energy was used 
for fragmentation. Peak lists were generated 
within PeakView by using the “create mgf 
file” script. MASCOT search engine with the 
following search parameters was used to 
identify peptides: no enzyme specificity, 
maximum of 4 miscleavages, oxidation as 
variable modification, peptide tolerance was 
set to 20 ppm and the MSMS tolerance to 
0.1Da. Data was searched against Swiss Prot 
database downloaded November 2016, 
restricted to proteins from humans only. 
   Peptides identified in the Mascot files were 
assessed for their potential allele binding 
specificity and affinity using the 
NetMHCcons 1.1 algorithm 
(21)(http://www.cbs.dtu.dk/services/NetMHC
cons/ ). Alleles HLA-A*02:01, -B*27:05 and 
–C*01:02 were selected for screening, using 
standard settings of 0.5% Rank and IC50 50 
nM for strong binders, and 2% Rank and 
IC50 500 nM for weak binders. Peptides 
identified as HLA-A*02:01, -B*27:05 and –
C*01:02 binders were tabulated, and Mann 
Whitney two tailed tests performed using 
Prism 7 (GraphPad Inc, US) software. Anchor 
motifs were analysed using Seq2Logo 
algorithm (22) 
(http://www.cbs.dtu.dk/biotools/Seq2Logo/ ), 
using the Shannon format and standard 
settings. 
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Figure Legends 
 
Table 1. Peptide identification and predicted binding affinities. The sequence of the identified 
peptides for cell and EV derived peptides eluted from HLA-A*02:01 and HLA-B*27:05 are 
shown in alphabetical order. Peptides in red are those detected in the EV pool only. Predicted 
binding affinities were generated using NetMHCcons 1.1. 
 
 
Figure 1. Characterisation of Jesthom EV. A, Cell lysates and EVs from Jesthom cells were 
immunoblotted for MHC class I (HC10), GRP78, CD9 and CD81. B, representative 
nanoparticle tracking analysis of culture supernatant from Jesthom cells, post 0.2 µm 
filtration, but prior to ultracentrifugation. C, Coommassie blue stained SDS-PAGE gel of 
approximately 2% of the washed W6/32 immunoisolation beads. Control beads (ctrl) received 
just lysis buffer. The W6/32 was not cross-linked and elutes from the beads with the MHC 
class I. D, Immunoblot of approximately 2% of the washed W6/32 immunoisolation beads, 
using anti HLA-B and –C antibody HC10. The second stage anti-IgG also recognises the IgH 
and IgL from W6/32 used in the immunoisolation step as indicated in C. 
 
Figure 2. Analysis of eluted HLA-A*02:01 and HLA-B*27:05 binding peptides. A and C, 
plot of predicted binding affinities (using NetMHCcons 1.1) for the cell and EV derived pools 
from HLA-A*02:01 and HLA-B*27:05. Data are shown as mean plus SEM (shown in red). 
Mann Whitney tests indicated no significant differences. B and D, plots of the peptide 
lengths, shown as a percentage of the whole pool for HLA-A*02:01 and HLA-B*27:05. E 
and F, Peptide anchor binding motifs (using Seq2Logo) for the 9 mer, 10 mer and 11 mer 
peptides from each of the cell and EV derived pools from HLA-A*02:01 and HLA-B*27:05. 
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B27	  cells	   nM	   B27	  EV	   nM	   A2	  cells	   nM	   A2	  EV	   nM	  
ARFLFTTGF 
ARFLLEGQVF 
ARFPETPAF 
ARFSPDGQYL 
ARIALLPLL 
ARIFQFQNF 
ARIPLNPVL 
ARLFIFETF 
ARLKEVLEY 
ARLPLVNSY 
ARLQTALLV 
ARLTDYVAF 
ARNKAITSL 
ARNLIYFGF 
ARNPPGFAF 
ARSPVAPAR 
ARSSVVTAV 
ARTPVMSTY 
ARTPVTSTY 
ARVKMQVTM 
ARVSIVNQY 
ARVYLNGDGM 
ARYGGSSNI 
ERLQYVFGY 
FRLFPVPGSGL 
GRAFLKRKEY 
GRAPISNPGM 
GRASPPPTY 
GRFGGNPGGF 
GRFGSGMNM 
GRFSSTTGLFY 
GRHAVVVGR 
GRHGVFLEL 
GRIDKPILK 
GRIGVITNR 
GRIKAIQLEY 
GRILSGVVTK 
GRIPGIYGR 
GRIVTIFAF 
GRLAHEVGWKY 
GRMEGPPPTY 
GRNSFEVRV 
36.12 
123.99 
277.63 
143.49 
34.77 
361.9 
122.66 
113.4 
302.73 
113.71 
89.62 
330.1 
147.43 
130.88 
418.82 
306.02 
540.07 
432.64 
605.05 
153.95 
307.68 
487.32 
270.22 
261.59 
106.56 
340.99 
253.23 
495.29 
81.75 
84.45 
220.01 
73.37 
71.79 
198.52 
138.91 
98.79 
132.31 
90.11 
74.97 
129.48 
95.63 
1050.6 
ARFLFTTGF 
ARFPETPAF 
ARFSPDGQYL 
ARIALLPLL 
ARIPLNPVL 
ARLFIFETF 
ARLKEVLEY 
ARLQTALLV 
ARNKAITSL 
ARNPPVVSK 
ARSPVAPAR 
ARTPVMSTY 
ARVSIVNQY 
ARVYLNGDGM 
ERLQYVFGY 
GRAFIFPSY 
GRAPISNPGM 
GRFGSGMNM 
GRFSGLLGR 
GRHAVVVGR 
GRIANTYNL 
GRIDKPILK 
GRIGQAIAR 
GRIKAIQLEY 
GRILSGVVTK 
GRIVTIFAF 
GRLGLVTSR 
GRNSFEVRV 
GRSEVIYNY 
GRSSVFSSR 
GRTFIQPNM 
GRTNLIVNY 
GRVFIIKSY 
GRVGTVIGSNK 
GRVGVITNR 
GRYAGGQGY 
GRYPGVSNY 
HRAQVIYTR 
HRFEQAFYTY 
HRFYGKNSSY 
HRLPPVTSF 
HRYGDGGSTF 
36.12 
277.63 
143.49 
34.77 
122.66 
113.1 
302.73 
89.62 
147.43 
243.82 
306.02 
432.64 
307.68 
487.32 
261.59 
78.29 
253.23 
84.85 
35.73 
73.37 
91.09 
198.52 
142.72 
98.79 
132.31 
74.97 
43.65 
1050.6 
265.87 
267.31 
249.16 
133.75 
147.43 
531.38 
222.4 
80.87 
193.22 
54.48 
47.34 
122 
98.79 
107.72 
AIAPIIAAV 
AISGIIMGI 
AIVDKVPSV 
ALAAALAHI 
ALADGVQKV 
ALDSQVPKV 
ALFQRPPLI 
ALIEKLVEL 
ALLAYTLGV 
ALMPVLNQV 
ALPPVLTTV 
ALSDSIHTV 
ALTSVVVTL 
ALWDIETGQQTV 
AMFDHIPVGV 
AMLRLIPSL 
AMPPPPPQGV 
AMWEHPITA 
AQLENPAAV 
FASHVSPEV 
FIDEYVETV 
FIIQGLRSV 
FIMIKNLLL 
FLADPSAFVAA 
FLDPRPLTVV 
FLDSTSPLL 
FLEKLLPPV 
FLLALEPEL 
FLLDEGRTIT 
FLLPILSQI 
FLSEEGGHVAV 
FLSELTQQL 
FLSTINVGL 
FLYTGEGDTV 
FMFDFDGDEIFHV 
FMLPDPQNISL 
FVFSFPVSV 
FVLPELPSV 
GIFGGHIRSV 
GLADNTVIAKV 
GLAPKPVQV 
GLATDVQTV 
13.2 
107.14 
15.45 
17.88 
8.2 
13.42 
53.61 
6.06 
5.1 
4.52 
12.71 
4.26 
41.35 
6.4 
3.89 
10.46 
323.04 
9.34 
33.3 
27.71 
4.13 
15.12 
42.94 
31.72 
9.6 
4.43 
4.04 
3.57 
230.98 
5.74 
24.87 
5.01 
7.6 
16.22 
2.52 
14.4 
4.62 
4.75 
99.86 
24.33 
40.9 
24.07 
AIAPIIAAV 
AIVDKVPSV 
ALADGVQKV 
ALAGHQDGITFI 
ALDSQVPKV 
ALDTVHVDPV 
ALLAYTLGV 
ALLDRIVSV 
ALMDEVVKA 
ALMPVLNQV 
ALSDSIHTV 
ALWDIETGQQTV 
AMWEHPITA 
FASHVSPEV 
FIYHGEVPQA 
FLANIGTSV 
FLDGNEMTL 
FLEKLLPPV 
FLNNQEYVL 
FLQEKSPAV 
FMATIAEGL 
FVLPELPSV 
GLAAGGIVAV 
GLAPKPVQV 
GLATDVQTV 
GLIDRQVTV 
GLMTTVHAI 
GLNEEIARV 
GLSTEGIYRV 
GLWEIENNPTV 
GQIEVVPEV 
HIIENIVAV 
HLLEEPIYL 
HLSIINEYL 
ILDQKINEV 
ILTDADPEV 
ILTDITKGV 
IMLEALERV 
ITYSQLITL 
KIYEGQVEV 
KLDQDLNEV 
KLFGMIITI 
13.2 
15.45 
8.2 
24.2 
13.42 
38.54 
5.1 
3.8 
7.6 
4.52 
4.26 
6.4 
9.34 
27.71 
53.03 
6.4 
14.55 
4.04 
19.81 
3.74 
9.65 
4.75 
21.37 
40.9 
24.07 
10.81 
10.3 
14.55 
24.73 
21.03 
4.15 
18.17 
7.6 
138.16 
13.42 
10.07 
37.71 
5.38 
312.72 
7.81 
11.05 
8.07 
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GRSAFIGIGF 
GRSEVIYNY 
GRTEVSFTL 
GRTFIQPNM 
GRTNLIVNY 
GRVALADIAF 
GRVFIIKSY 
GRVGTVIGSNK 
GRVGVITNR 
GRWPGSSLYY 
GRWQYPLIY 
GRYAGGQGY 
GRYPGVSNY 
GRYQVSWSL 
HRAQVIYTR 
HRDSHITNL 
HRFEQAFYTY 
HRFYGKNSSY 
HRIKDYHSY 
HRITIKKRF 
HRLPPVTSF 
HRNEVTVEL 
HRYGDGGSTF 
IRAAPPPLF 
IRLPSQYNF 
IRNAHSIHQR 
KRAALQALK 
KRFADEGTVVKR 
KRFEHSAKL 
KRFEQEINAKK 
KRFGKAYNL 
KRFKEANNF 
KRFKVSDEVGF 
KRFQVAVNL 
KRHNYVRKV 
KRIDIIHNL 
KRLDINTNTY 
KRLDVTVQSF 
KRLGTLVVTY 
KRMNPNSPSITY 
KRNDYVHAL 
KRNPGVKEGY 
KRQAIKTAF 
KRTSIETNV 
107.14 
265.87 
212.98 
249.16 
133.75 
254.61 
147.43 
531.38 
222.4 
54.78 
37.71 
80.87 
193.22 
34.77 
54.48 
1091.15 
47.34 
122 
253.23 
211.83 
98.79 
388.27 
107.72 
243.82 
291.48 
471.75 
27.71 
74.57 
54.48 
170.61 
22.56 
234.76 
260.18 
37.71 
149.84 
46.57 
134.47 
60.71 
44.12 
81.75 
69.88 
484.69 
98.79 
995.27 
IRAAPPPLF 
IRLPSQYNF 
IRNAHSIHQR 
KRFEELTNL 
KRFEQEINAKK 
KRFKEANNF 
KRFQVAVNL 
KRIKPRPERF 
KRLASSVLR 
KRLDINTNTY 
KRLSKVVNI 
KRNPGVKEGY 
KRWQGGERSM 
KRYKSIVKY 
LRFQSSAVM 
LRNPLIAGK 
LRNQSVFNF 
NRFAGFGIGL 
QRAAVIERF 
QRFPLSFGF 
QRNEVVVEL 
QRQDIAFAY 
QRTDVLTGL 
RRFSPIPFPPLSY 
RRFTEIYEF 
RRFVNVVPTF 
RRFVNVVPTFGK 
RRIKEIVKKH 
RRISGVDRYY 
RRLALFPGVA 
RRLGLALGL 
RRLPSDVVTGY 
RRLSELLRY 
RRLSYNTASNK 
RRMGPPVGGHR 
RRMGPPVGGHRR 
RRNGTLPWLR 
RRNPYFRNK 
RRSDVEILGY 
RRSKEITVR 
RRVNTTQKRY 
SRFLMPEAY 
SRIHPVSTM 
SRLAHYNKR 
243.82 
291.48 
471.75 
111.88 
170.61 
234.76 
37.71 
87.7 
54.19 
134.47 
115.57 
484.69 
31.38 
71.79 
270.22 
110.08 
522.82 
83.54 
189.08 
50.78 
759.4 
337.32 
719.41 
26.25 
18.47 
14.55 
14.48 
104.28 
66.56 
32.77 
9.39 
133.03 
38.33 
67.28 
67.65 
21.49 
28.62 
55.08 
90.6 
141.18 
102.05 
192.18 
236.04 
328.32 
GLDGPPPTV 
GLDRNAPSV 
GLIDRQVTV 
GLIGVGLINV 
GLLGNVAEV 
GLSQVAVTV 
GLWEIENNPTV 
GLWGQSVPTA 
GQIEVVPEV 
HIIENIVAV 
HLLEEPIYL 
HLSIINEYL 
ILDKKVEKV 
ILDQKINEV 
ILDVTVVYL 
ILTDITKGV 
ILTETINTV 
IMLEALERV 
IQDNHDGTYTV 
KIGTYFRV 
KIYEGQVEV 
KLADFGDAVQL 
KLAENIDAQL 
KLDQDLNEV 
KLFGMIITI 
KLGSVPVTV 
KLIDGQVIQL 
KLIPQLPTL 
KLLDISELDMV 
KLLDPEDVAVQL 
KLLQFYPSL 
KLNPQQFEV 
KLYAGAILEV 
KVLGIVVGV 
LLDRFLATV 
LLDVPTAAV 
LLGPPPVGV 
LLIDDKGTIKL 
LLIENVASL 
LLIPGLATA 
LLISGLPTI 
LLLDVPTAAVQA 
LLMLDVMII 
LLPEGPPAI 
51.34 
59.73 
10.81 
18.87 
8.2 
44.6 
21.03 
51.06 
4.15 
18.17 
7.6 
138.16 
75.79 
13.42 
31.89 
37.71 
11.98 
5.38 
409.85 
212.98 
7.81 
52.18 
26.25 
11.05 
8.07 
21.96 
11.66 
6.03 
9.81 
24.73 
6.94 
6.71 
4.67 
13.13 
9.54 
28.78 
72.97 
84.9 
8.34 
13.57 
5.87 
32.59 
37.51 
25.55 
KLHGVNINV 
KLLDPEDVAVQL 
KLSGSLVAKL 
LLDSAPLNV 
LLDVPTAAV 
LLGPPPVGV 
LLIENVASL 
LLLDVPTAAV 
LLPPAPPHA 
LMDHTIPEV 
LMVDHVTEV 
MLPPPPLTA 
QLSEVFIQL 
QLVDIIEKV 
RLIQESPTL 
RLNEAAVTV 
RLPEAIEEV 
RLQEDPPAGV 
RLQEDPPVGV 
RLQEEINEV 
SIIGRLLEV 
SLADLQNDEV 
SLAEVAGLQV 
SLAQYLINV 
SLAQYNPKL 
SLAVADLTFV 
SLDQPTQTV 
SLHDIQLSL 
SLINVGLISV 
SLLDPVPEV 
SLLDRFLATV 
SLLENLEKI 
SLLEVNEESTV 
SLLGGDVVSV 
SLLPEGPPAI 
SLLPPDALVGL 
SLLQTLYKV 
SLMLVTVEL 
SLSPIYPAA 
SLWGQPAEA 
SLYDYNPNL 
SMADIPLGFGV 
SMSADVPLV 
SVIEQIVYV 
16.84 
24.73 
54.48 
20.14 
28.78 
72.97 
8.34 
7.73 
245.15 
3.8 
3.55 
263.01 
23.94 
21.25 
50.51 
16.31 
8.52 
44.6 
42.25 
9.91 
18.27 
35.34 
35.15 
4.65 
20.47 
17.59 
91.58 
24.47 
11.47 
3.31 
5.8 
21.03 
27.11 
9.49 
28.47 
51.89 
6.75 
12.51 
41.12 
51.61 
3.43 
16.39 
5.47 
6.06 
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KRYAVPSAGL 
KRYKSIVKY 
LRFEVVPSKF 
LRFQSSAVM 
LRNPLIAGK 
LRNQSVFNF 
NRFAGFGIGL 
NRLPLVVSF 
QRAAVIERF 
QRFPLSFGF 
QRHSFQISL 
QRIDLAVLL 
QRIYLVTTY 
QRNEVVVEL 
QRQDIAFAY 
QRTDVLTGL 
QRVSIFFDY 
QRYPNPYSK 
RQTGIVLNR 
RRAKLKADRY 
RRAQLQYVQR 
RRDVQKVVGF 
RRFFPYYVY 
RRFSPIPFPPLSY 
RRFVNVVPTF 
RRIKEIVKKH 
RRISGVDRYY 
RRLPSDVVTGY 
RRMGPPVGGH 
RRMGPPVGGHR 
RRMGPPVGGHRR 
RRWLPAGDAL 
RRYFGGTEDRL 
SRAKVKFNV 
SRFLMPEAY 
SRFQGTLYL 
SRFSLENNF 
SRIPFNQALVF 
SRLAHYNKR 
SRLATLNEK 
SRLGLPLLL 
SRLPSLGAGF 
SRLSIPTYGL 
SRLYIAYQF 
33.48 
71.79 
95.12 
270.22 
110.08 
522.82 
83.54 
141.95 
189.08 
50.78 
105.42 
116.83 
175.29 
759.4 
337.32 
719.41 
595.31 
89.62 
187.05 
71.41 
34.59 
207.3 
41.8 
26.25 
14.55 
104.28 
66.56 
133.03 
44.6 
67.65 
21.49 
16.22 
90.6 
917.7 
192.18 
56.28 
361.9 
331.89 
328.32 
198.52 
31.38 
197.45 
60.06 
52.74 
SRLGLPLLL 
SRNEGVATY 
SRTSVQPTF 
SRTVVYITY 
SRVKLILEY 
SRYQGVNLY 
TRYQGVNLY 
YRFLPQKIIYL 
	  
31.38 
1229.06 
437.34 
700.21 
166.06 
181.07 
384.09 
63.39 
	  
LLPPAPPHA 
LMDHTIPEV 
LMVDHVTEV 
MLFPGSIAL 
MLPPPPLTA 
MLYDIVPVV 
NLASFIEQV 
NLIDLDDLYV 
NLLPKLHIV 
NMVAKVDEV 
QLLDQVEQI 
QLLEKVPTL 
QLVDIIEKV 
QVFPGLLERV 
RLFDQAFGL 
RLIEESVTV 
RLLDYVVNI 
RLLEIDPYL 
RLMNETTAV 
RLPEAIEEV 
RLQEDPPAGV 
RLQEDPPVGV 
RLQEEINEV 
RLWGEPVNL 
RLYPWGVVEV 
RQLEEEGITFV 
RVFENIVAV 
RVIGTLEEV 
RVLDPSMVILEV 
SIIGRLLEV 
SILEDPPSI 
SLAEVAGLQV 
SLAQYLINV 
SLAQYNPKL 
SLDQPTQTV 
SLHDIQLSL 
SLINVGLISV 
SLLDPVPEV 
SLLDRFLATV 
SLLENLEKI 
SLLEVNEESTV 
SLLGGDVVSV 
SLLPEGPPAI 
SLLPPDALVGL 
245.15 
3.8 
3.55 
4.78 
263.01 
2.78 
10.87 
11.6 
17.21 
57.51 
53.32 
11.41 
21.25 
188.06 
4.02 
6.82 
3.74 
4.02 
6.94 
8.52 
44.6 
42.25 
9.91 
30.54 
6.5 
64.08 
10.07 
48.11 
47.34 
18.27 
64.43 
35.15 
4.65 
20.47 
91.58 
24.47 
11.47 
3.31 
5.8 
21.03 
27.11 
9.49 
28.47 
51.89 
TLFDYEVRL 
TLWVDPYEV 
TLYEAVREV 
TVLPFVSTV 
VLIDYQRNV 
VLIEGSINSV 
VLIETLVTL 
VLIPKLPQL 
VMDSKIVQV 
YLADVTNAL 
YLDPAQRGV 
YLGDVSERV 
YLLPAIVHI 
YLLTHPPPIM 
YLPEDFIRV 
YLTNEGIQYL 
YLYCTFISL 
YQVGQLYSV 
YTSPVNPAV 	  
8.57 
6.4 
11.17 
40.68 
11.53 
6.43 
10.75 
10.75 
10.46 
3.51 
24.87 
7.24 
3.76 
31.89 
3.99 
11.6 
5.35 
3.72 
33.3 	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SRNAQTFGF 
SRNEGVATY 
SRNGVITQY 
SRNSNTVVFVK 
SRSNTQPGF 
SRTSVQPTF 
SRVKLILEY 
SRWEKVVQR 
SRYQGVNLY 
TRIQNPSAYAK 
TRSGAIFTK 
TRYQGVNLY 
VRFYIESISY 
YRFFLGNQF 
YRLGNVDAFQL 
	  
191.14 
1229.06 
405.44 
723.31 
543 
437.34 
166.06 
93.59 
181.07 
979.25 
238.6 
384.09 
267.31 
42.71 
61.37 
	  
SLLQTLYKV 
SLMLVTVEL 
SLPDFGISYV 
SLSPIYPAA 
SLSQTPPRV 
SLWGQPAEA 
SLYDYNPNL 
SLYGGTITI 
SMADIPLGFGV 
SMSADVPLV 
SMYDKVLML 
SQTFVNPHV 
SVIEQIVYV 
TLFDYEVRL 
TLIEDILGV 
TLIGLSIKV 
TLWVDPYEV 
TLYEAVREV 
VLFENTDSVHL 
VLIDVGTGYYV 
VLIDYQRNV 
VLIEGSINSV 
VLIPKLPQL 
VLLDAPIQL 
VLLGKVYVV 
VLMTEDIKL 
VLQDIQVML 
VLWDRTFSL 
VMDSKIVQV 
YLADVTNAL 
YLGQVTTI 
YLIEPDVEL 
YLLDQHILI 
YLLEQTPEQQA 
YLLPAIVHI 
YLLQEPPRTV 
YLPEDFIRV 
YLSKIIPAL 
YLTHDSPSV 
YLTNEGIQYL 
YLYPDITRL 
YQVGQLYSV 	  
6.75 
12.51 
6.22 
41.12 
75.79 
51.61 
3.43 
19.28 
16.39 
5.47 
10.58 
358.01 
6.06 
8.57 
4.36 
15.61 
6.4 
11.17 
21.72 
10.07 
11.53 
6.43 
10.75 
8.43 
6.43 
54.78 
21.72 
3.43 
10.46 
3.51 
52.74 
5.99 
4.4 
25.55 
3.76 
13.57 
3.99 
4.29 
5.29 
11.6 
4.06 
3.72 	  	  Table	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  Figure	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  Figure	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